AeroLeads people directory · profile
Fatih M. Uckun, M.D., Ph.D Email & Phone Number
Head of Immuno-Oncology and Chief Medical and Chief Scientific Officer;
at
Ares Pharmaceuticals, LLC
1 work email found
@comcast.net
4 phones found area 612 and 213
LinkedIn matched
✓ Verified August 2026
4 data sources
Profile completeness 100%
Current company
Role
Head of Immuno-Oncology and Chief Medical and Chief Scientific Officer;
Location
Beverly Hills, California, United States
Company size
Who is Fatih M. Uckun, M.D., Ph.D? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Fatih M. Uckun, M.D., Ph.D is listed as Head of Immuno-Oncology and Chief Medical and Chief Scientific Officer; at Ares Pharmaceuticals, LLC, a with 3 employees, based in Beverly Hills, California, United States. AeroLeads shows a work email signal at comcast.net, phone signal with area code 612, 213, and a matched LinkedIn profile for Fatih M. Uckun, M.D., Ph.D.
Fatih M. Uckun, M.D., Ph.D previously worked as Head of Immuno-Oncology and Chief Medical/Chief Scientific Officer; at Ares Pharmaceuticals, Llc and Head of Strategy for Clinical Development and Translational Hematology-Oncology at Aresmit Biomedical Computational Strategies (A.B.C.S). Fatih M. Uckun, M.D., Ph.D holds M.D. And Dr. Med, Internal Medicine from Heidelberg University.
Company email context
Email format at Ares Pharmaceuticals, LLC
This section adds company-level context without repeating Fatih M. Uckun, M.D., Ph.D's masked contact details.
*@comcast.net
68% confidence
AeroLeads found 1 current-domain work email signal for Fatih M. Uckun, M.D., Ph.D. Compare company email patterns before reaching out.
Profile bio
About Fatih M. Uckun, M.D., Ph.D
Fatih M. Uckun, M.D., Ph.D, is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations, including ASCO, ASH and AACR. Dr. Uckun is a Principal Member of the Turkish Academy of Sciences/TUBA (a Member of the European Federation of Academies of Sciences and Humanities/ALLEA and Association of Academies and Societies of Sciences in Asia/AASSA). He earned his doctoral degrees at University of Heidelberg in Germany and completed his residency training in Pediatrics, fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology at the University of Minnesota in the US. Dr. Uckun has more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals in oncology/immuno-oncology as well as infectious diseases and immunology. Dr. Uckun worked 11 years as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy. He worked 6 years as a Professor and Head of Translational Research in Leukemia and Lymphoma of the CCBD and a Principal Investigator of the Stem Cell-Regenerative Medicine Initiative at the at the University of Southern California. He has held executive positions in multiple biotechnology companies and has extensive regulatory experience. He has published more than 500 peer-reviewed papers and he has authored numerous review articles and book chapters. He received numerous awards including the Stohlman Memorial Award of the Leukemia Society of America (now known as the Leukemia and Lymphoma Society/LLS), the highest honor given to a Leukemia Society Scholar. He has served as a member of several editorial boards and NIH grant review/special emphasis panels.In addition, Dr. Uckun has deep knowledge and 20+ years of experience in treatment of infectious diseases and their complications. He served as a Defense Advanced Research Projects Agency (DARPA) PI and directed a universal virus neutralizer program project as part of a countermeasures initiative against viruses that can be used as bioweapons. https://www.researchgate.net/profile/Fatih_Uckunhttps://loop.frontiersin.org/people/679873/biohttps://orcid.org/0000-0001-9334-183Xhttps://sciprofiles.com/profile/fatihuckun
Listed skills include Translational Research, Public Speaking, Cancer, Immunology, and 47 others.
Current workplace
Fatih M. Uckun, M.D., Ph.D's current company
Company context helps verify the profile and gives searchers a useful next step.
Ares Pharmaceuticals, Llc
Employees
3
AeroLeads page
21 roles · 41 years
Fatih M. Uckun, M.D., Ph.D work experience
A career timeline built from the work history available for this profile.
Head Of Immuno-Oncology And Chief Medical/Chief Scientific Officer;
Current
Jul 2015 - Present
Head Of Strategy For Clinical Development And Translational Hematology-Oncology
Current
Jan 2017 - Present
May 2022 - Feb 2023
Exec Vice President, Global Head Of Clinical And Medical Affairs; Chief Medical & Scientific Officer
As Executive Vice President, Clinical Affairs, Global Head of Clinical and Medical Affairs, and Chief Scientific Officer, Dr. Uckun’s responsibilities include providing medical-scientific leadership and direction for Reven’s pipeline of clinical development programs in sepsis, metabolic disorders, inflammatory disorders, including but not limited to non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NASH), iatrogenic organ toxicity, including chemotherapy-induced liver toxicity, and translational oncology as well as contributing to the strategy, direction and execution of the company's clinical development plans. Dr. Uckun will coordinate collaborations with academic centers and other biotech and pharmaceutical companies and provide day-to-day oversight for internal research, research and development, regulatory, safety as well as clinical operations teams.
Jun 2020 - Mar 2022
Consultant; Chief Clinical Advisor
As a consultant to the Aptevo leadership, Dr. Uckun provides subject matter expertise in design of patient-centric clinical trials in acute leukemia patients. In collaboration with other leukemia experts at academic health centers in the US and Europe, he contributes to the design of clinical research protocols to evaluate Aptevo's bispecific antibodies as components of innovative multi-modality regimens that may improve the outcome of adult and pediatric acute leukemia patients.
Mar 2021 - Dec 2021
Vice President And Clinical Strategy Lead, Oncology-Hematology, Member Of Covid-19 Task Force
Jan 2020 - Jun 2020
Chief Medical Officer
Oncotelic, Inc.
http://oncotelic.com/management/
Jan 2019 - Jan 2020
Chief Medical Officer
In April 2019. Mateon Therapeutics, Inc. (OTCQB:MATN) and Oncotelic Inc. have completed their merger and created a new immuno-oncology company with a late-stage clinical asset against cancer and a promising product pipeline. In connection with the merger, Oncotelic, Inc. has become a wholly owned subsidiary of Mateon, with the former Oncotelic shareholders receiving a combination of common and preferred stock in Mateon representing approximately 85% of Mateon’s outstanding equity. Mateon’s prior stockholders retain approximately 15% of the outstanding equity.
Jan 2019 - Jan 2020
Executive Medical Director, Global Oncology & Hematology
Function as a senior strategy advisor in Clinical Development, Global Oncology and Hematology with an emphasis on advanced solid tumors and relapsed or therapy-refractory hematologic malignanciesContribute to design of clinical path for small molecules as well as biologics with an emphasis on immuno-oncology drugs. Contribute to regulatory strategy for clinical development of multiple drug candidates, including targeted therapeutics, therapeutic vaccines, immuno-modulators, cytotoxic agents, immuno-oncology drugs. Contribute to biomarker identification and design of biomarker-guided clinical trialshttps://www.syneoshealth.com/
Sep 2017 - Nov 2018
Professor
Professor of Research Pediatrics, Department of Pediatrics at USC Keck School of MedicineMember, Developmental Therapeutics Program, Norris Comprehensive Cancer Center
Jul 2009 - Jun 2015
Principal Investigator; Usc Stem Cell Regenerative Medicine Initiative
Hematopoietic stem cell research
Jul 2013 - May 2015
Member, Norris Comprehensive Cancer Center
Translational cancer research
Jan 2010 - May 2015
Professor Research Pediatrics And Head, Translational Research In Leukemia And Lymphoma At The Cccbd
Professor Research PediatricsHead, Translational Research in Leukemia and Lymphoma
Jul 2009 - Jun 2015
Director, Research (Also Served As The Founding President/Ceo Of Its Spin-Off Biotech Companies)
Drug Discovery Enterprises (Dba Parker Hughes Institute)
A 501(c)3 research organization that was formed to discover new drug candidates against cancer. Spin off companies included Alexander Parker Corporation, Paradigm Pharmaceuticals, Jupiter Research.
1997 - 2008
~11 yrs
President/Cso
Paradigm Pharmaceuticals Llc
Coordinated target validation, portfolio prioritization, and drug discovery/development efforts in oncology and infectious diseases.
Oct 2002 - Feb 2007
President/Cso
Alexander Parker Corporation
Coordinated the CRO function of the company for the Drug Discovery Enterprises, Inc(dba Parker Hughes Institute). Served as the lead FDA contact and IND Investigator-Sponsor for Phase 1, Phase 2 and randomized Phase 2 clinical trials of immuno-oncology products. Served as the lead contact for the Childrens Cancer Study Group for groupwide clinical testing of anti-CD19 immunoconjugates.Select references:Seibel NL, Sather H, Steinherz PG, De Laat C, Ettinger LJ, Freyer D, et al. Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL. Children's Cancer Group. Blood. 1961;2000;96:721a.Seibel NL, Krailo M, O'Neill K, Franklin J, Uckun F, Reaman GH. Phase I study of B43-PAP immunotoxin in combination with standard 4-drug induction for patients with CD19+ acute lymphoblastic leukemia (ALL) in relapse, a Children's Cancer Group Study. Pediatric Research. 1999;45:5. Abstract 195.
1995 - 2000
~5 yrs
Director Of Biotherapy Institute
Directed translational biotherapy research on immunoconjugates, monoclonal antibodies, fusion toxins, and cytokine-drug conjugates. Reported to Provost of Academic Health Center and coordinated clinical and laboratory research efforts funded by multiple NIH grants.
1995 - 1997
~2 yrs
Full Professor (With Tenure)
Conducted research and patient care and education
1993 - 1997
~4 yrs
Associate Professor (With Tenure)
Conducted research and patient care and education
1990 - 1992
~2 yrs
1986 - 1989
~3 yrs
2 education records
Fatih M. Uckun, M.D., Ph.D education
M.D. And Dr. Med, Internal Medicine
Heidelberg University
Pediatrics Residency; Fellowship In Hematology/Oncology; Postdoctoral Fellowship In Immunology/Bmt
University Of Minnesota Medical School
FAQ
Frequently asked questions about Fatih M. Uckun, M.D., Ph.D
Quick answers generated from the profile data available on this page.
What company does Fatih M. Uckun, M.D., Ph.D work for?
Fatih M. Uckun, M.D., Ph.D works for Ares Pharmaceuticals, LLC.
What is Fatih M. Uckun, M.D., Ph.D's role at Ares Pharmaceuticals, LLC?
Fatih M. Uckun, M.D., Ph.D is listed as Head of Immuno-Oncology and Chief Medical and Chief Scientific Officer; at Ares Pharmaceuticals, LLC.
What is Fatih M. Uckun, M.D., Ph.D's email address?
AeroLeads has found 1 work email signal at @comcast.net for Fatih M. Uckun, M.D., Ph.D at Ares Pharmaceuticals, LLC.
What is Fatih M. Uckun, M.D., Ph.D's phone number?
AeroLeads has found 4 phone signal(s) with area code 612, 213 for Fatih M. Uckun, M.D., Ph.D at Ares Pharmaceuticals, LLC.
Where is Fatih M. Uckun, M.D., Ph.D based?
Fatih M. Uckun, M.D., Ph.D is based in Beverly Hills, California, United States while working with Ares Pharmaceuticals, LLC.
What companies has Fatih M. Uckun, M.D., Ph.D worked for?
Fatih M. Uckun, M.D., Ph.D has worked for Ares Pharmaceuticals, Llc, Aresmit Biomedical Computational Strategies (A.B.C.S), Oncotelic, Reven Pharmaceuticals, and Aptevo Therapeutics Inc.
How can I contact Fatih M. Uckun, M.D., Ph.D?
You can use AeroLeads to view verified contact signals for Fatih M. Uckun, M.D., Ph.D at Ares Pharmaceuticals, LLC, including work email, phone, and LinkedIn data when available.
What schools did Fatih M. Uckun, M.D., Ph.D attend?
Fatih M. Uckun, M.D., Ph.D holds M.D. And Dr. Med, Internal Medicine from Heidelberg University.
What skills is Fatih M. Uckun, M.D., Ph.D known for?
Fatih M. Uckun, M.D., Ph.D is listed with skills including Translational Research, Public Speaking, Cancer, Immunology, Clinical Research, Cancer Research, Cell, and Cell Biology.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial